Development
Acrivon Therapeutics, Inc.
ACRV
$1.35
$0.108.00%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -14.47M | -13.91M | -12.76M | -8.93M | -9.20M |
| Total Depreciation and Amortization | 133.00K | 129.00K | 125.00K | 125.00K | 116.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.68M | 2.11M | 1.70M | 1.32M | 269.00K |
| Change in Net Operating Assets | 1.84M | 2.56M | -430.00K | -1.87M | 2.29M |
| Cash from Operations | -9.81M | -9.11M | -11.36M | -9.35M | -6.52M |
| Capital Expenditure | 0.00 | -112.00K | -25.00K | -251.00K | -426.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1.52M | 19.45M | 9.35M | -94.82M | -44.69M |
| Cash from Investing | 1.52M | 19.34M | 9.33M | -95.07M | -45.12M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 78.00K | 379.00K | -- | 104.46M | 24.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -2.60M | -164.00K |
| Cash from Financing | 78.00K | 379.00K | -- | 101.86M | -140.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -8.21M | 10.61M | -2.03M | -2.56M | -51.78M |